Thermo Fisher Scientific, Inc.
TMO
$0.00
-0.62%
Thermo Fisher Scientific is a global leader in the Medical - Diagnostics & Research industry, providing scientific instruments, laboratory equipment, and life science reagents. The company is defined by its comprehensive portfolio across four key segments, positioning it as an essential partner in scientific discovery and healthcare.…
TMO
Thermo Fisher Scientific, Inc.
$0.00
TMO 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Thermo Fisher Scientific, Inc.'s 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
13 analysts
Implied Upside
—
vs. current price
Analyst Count
13
covering this stock
Price Range
$0 - $0
Analyst target range
Wall Street analysts maintain a bullish consensus on Thermo Fisher, with recent actions from 13 tracked firms including upgrades from Citigroup and Keybanc. The consensus estimates project an average EPS of $36.24 and average revenue of $57.24 billion for the upcoming period. The predominant ratings are 'Buy' or 'Overweight,' indicating strong institutional confidence in the company's outlook.
TMO Technical Analysis
The stock's overall trend has been negative over the past six months, with the price declining from $579.45 on December 31, 2025, to $491.53 on March 31, 2026, representing a 15.2% drop. Short-term performance shows significant weakness, with a 1-month decline of 5.7% and a 3-month decline of 15.2%, both underperforming the S&P 500 by 0.4 and 10.5 percentage points, respectively. The current price of $491.53 sits near the lower end of its 52-week range of $385.46 to $643.99, approximately 23.6% below the high, indicating the stock is in a corrective phase.
Beta
0.97
0.97x market volatility
Max Drawdown
-27.4%
Largest decline past year
52-Week Range
$385-$644
Price range past year
Annual Return
+0.5%
Cumulative gain past year
| Period | TMO Return | S&P 500 |
|---|---|---|
| 1m | -3.3% | -4.3% |
| 3m | -17.1% | -4.0% |
| 6m | -9.5% | -2.0% |
| 1y | +0.5% | +22.2% |
| ytd | -17.1% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMO Fundamental Analysis
Revenue growth remains positive, with Q4 2025 revenue of $12.22 billion representing a 7.2% year-over-year increase from the same quarter in 2024. Profitability is solid, with a net margin of 16.2% in the latest quarter, supported by a gross margin of 38.0% and an operating margin of 18.8%. Financial health is manageable with a debt-to-equity ratio of 0.76 and a strong current ratio of 1.89, while the company generated robust free cash flow of $6.29 billion over the trailing twelve months. Operational efficiency is adequate, with a return on equity (ROE) of 12.6% and a return on assets (ROA) of 5.0%, though asset turnover metrics suggest room for improvement.
Quarterly Revenue
$12.2B
2025-12
Revenue YoY Growth
+0.07%
YoY Comparison
Gross Margin
+0.37%
Latest Quarter
Free Cash Flow
$6.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMO Overvalued?
Given the company's positive net income, the primary valuation metric is the P/E ratio. The trailing P/E ratio is 32.3, while the forward P/E is 18.3 based on estimated EPS of $36.24. The PEG ratio of 4.51 suggests the stock may be richly valued relative to its earnings growth expectations. Peer comparison data is not available in the provided inputs, so a direct industry average comparison cannot be made.
PE
32.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~43x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.7x
Enterprise Value Multiple